No OS benefit? No problem. FDA panel backs use of Lynparza in pancreatic cancer
As AstraZeneca works to tighten its hold on the PARP market, an independent panel of advisors to the FDA cautiously endorsed Lynparza’s use in certain pancreatic cancer patients, even though it failed to help patients live longer.
On Tuesday, panelists voted 7-5 to recommend the drug for maintenance use in patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas, whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy. Globally, germline BRCAm pancreatic cancer accounts for 5-7% of all cases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
